Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q8NEV4
UPID:
MYO3A_HUMAN
Alternative names:
-
Alternative UPACC:
Q8NEV4; Q4G0X2; Q5VZ28; Q8WX17; Q9NYS8
Background:
Myosin-IIIa, encoded by the gene with accession number Q8NEV4, is a probable actin-based motor protein that exhibits protein kinase activity. It is crucial for normal cochlear hair bundle development and hearing, playing a significant role in the early steps of cochlear hair bundle morphogenesis. Myosin-IIIa influences the number and lengths of stereocilia and limits the growth of microvilli within the forming auditory hair bundles, contributing to the hair bundle's architecture, including its staircase pattern.
Therapeutic significance:
Myosin-IIIa's involvement in Deafness, autosomal recessive, 30, characterized by bilateral progressive hearing loss, underscores its therapeutic significance. Understanding the role of Myosin-IIIa could open doors to potential therapeutic strategies for hearing loss conditions.